関連する実験動画
冠動脈疾患における7つの血静性遺伝子ポリモルフィズム:66155例と91307例の対照群のメタ分析
Zheng Ye1, Eugene H C Liu, Julian P T Higgins
1Department of Public Health and Primary Care, University of Cambridge, Strangeways Site, Wort's Causeway, Cambridge CB1 8RN, UK.
Lancet (London, England)
|March 1, 2006
まとめ
V因子 (リーデン) とプロトロンビンの特定の遺伝的変異は,冠動脈疾患のリスクを適度に増加させる可能性があります. これらの関連性を確認し,プロトロンボティック現象型に対する治療効果を探るためには,さらなる研究が必要である.
科学分野:
- 遺伝学 遺伝学とは
- 心血管医学 心血管医学
- トロンボシス (Thrombosis) とは
背景:
- 血液静止遺伝子の変異は静脈血栓症と関連しています.
- 冠動脈疾患 (CAD) のこれらの変種に関する以前の研究では,矛盾する結果が得られました.
- これらの関連性を明らかにするために,大規模なメタ分析が必要である.
研究 の 目的:
- 7つの一般的な血液静止遺伝子変異と冠動脈疾患のリスクとの関連性をメタ分析する.
- これらの関連における異質性の潜在的な原因を調査する.
- CADの病原性におけるこれらの変種の役割に関する堅実な証拠を提供するためです.
主な方法:
- 66,155人のCAD症例と91,307人のコントロールを含む191件の研究のメタ分析.
- 試験された変種:ファクターV G1691A (リーデン),ファクターVII G10976A,プロトロンビンG20210A,PAI-1 [-675] 4G/5G,GPIa C807T,GPIbalpha T[-5]C,およびGPIIIa C1565T. 試験した変種
- 探求された異質性と出版バイアス.
主要な成果:
- ファクターV 1691A (リーデン) とプロトロンビン20210Aの変種は,中等度のCADリスク増加との関連を示した (RR 1.17と1.31).
- PAI-1 [-675] 4Gの変種は軽度の関連性 (RR 1.06),出版バイアスの兆候を示した.
- 因子VII,GPIa,GPIbalpha,GPIIIaの変異は,CADと有意な関連性を示さなかった.
結論:
- V因子1691Aおよびプロトロンビン20210Aの変種は,中等度の冠動脈疾患リスクと関連している可能性があります.
- これらの変異は,循環するトロンビン生成を増加させる.
- 遺伝子-遺伝子/環境の相互作用と,プロトロンボティック現象型を標的とした潜在的な治療戦略を探求するためのさらなる研究は正当化されています.
関連する概念動画
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...